Establishing a comprehensive tissue archive for multi-center prospective longitudinal and cohort studies - Step 1: Prostate cancer - Validation of the HistoBest Biopsy Chip(TM) (patent pending) as a diagnostic tool and enabling technology in the screening for retroviruses, genetic susceptibility and somatic mutations

Not Applicable

Recruiting

• Conditions: prostate cancer; Renal and Urogenital - Other renal and urogenital disorders

• Registration Number: ACTRN12611001242910
• Lead Sponsor: MedNewLife Medical Center

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2011-12-06
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: Male
• Target Recruitment: 100

Inclusion Criteria

clinical/biochemical suspicion of prostate cancer
(positive digital rectal examination - DRE and/or
prostate specific antigen - PSA >= 2.5 ng/ml)

Exclusion Criteria

There are no exclusion criteria

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
presence of cancer (Y/N)[at diagnosis]

Secondary Outcome Measures

Name	Time	Method
location of cancer (location of positive prostate biopsy cores)[at diagnosis];extension of cancer (in mm and % of length of each biopsy core)[at diagnosis];grade of cancer (Gleason score)[at diagnosis]